RxDoctor Payments Data

Ann Dipaolo, DO

Family Medicine · Forked River, NJNPI 1285604041

Payments from drug & device makers

$2,500in general payments, 2019–2025

Across 132 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$331
  • AbbVie$307
  • Amgen$236
  • Lilly USA, LLC$166
  • GSK$109
  • plus $351 from 10 others

What the payments were for

  • Food & beverage$2,500100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,500 in reported general payments places this provider in the 80th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$212,564
Medicare patients
267
Services billed
2,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide50$58,109
JanuviaSitagliptin Phosphate46$47,142
JardianceEmpagliflozin35$28,788
FarxigaDapagliflozin Propanediol15$18,721
VascepaIcosapent Ethyl23$15,273
EliquisApixaban17$14,448
MyrbetriqMirabegron11$14,439
QuliptaAtogepant12$12,711
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,914
Icosapent Ethyl24$8,148
Albuterol Sulfate HfaAlbuterol Sulfate163$4,423
Atorvastatin Calcium326$4,029
SynthroidLevothyroxine Sodium47$3,762
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,678
Rosuvastatin Calcium185$3,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$166$58,10950 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,000$29,63531 claims
Boehringer IngelheimJardiance$26$28,78835 claims
AbbVieQulipta, Synthroid$307$16,47359 claims
PfizerEliquis$64$14,44817 claims
Astellas Pharma US IncMyrbetriq$15$14,43911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Forked River

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →